Successful treatment of metastatic colorectal cancer with synchronous BRAF V600E mutation and dMMR with BGB-A317

被引：2

作者：

Cheng, Yi ^{[1
]}

Fang, Xue-Feng ^{[1
]}

Hu, Han-Guang ^{[1
]}

Wang, Jiang ^{[2
]}

Sun, Li-Feng ^{[2
]}

Yuan, Ying ^{[1
,3
,4
]}

机构：

[1] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Med Oncol, Hangzhou 310009, Zhejiang, Peoples R China

[2] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Colorectal Surg, Hangzhou 310009, Zhejiang, Peoples R China

[3] Zhejiang Univ, Sch Med, Chinese Natl Minist Educ, Canc Inst,Key Lab Canc Prevent & Intervent, Hangzhou 310009, Zhejiang, Peoples R China

[4] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Key Lab Mol Biol Med Sci, Hangzhou 310009, Zhejiang, Peoples R China

来源：

IMMUNOTHERAPY | 2020年 / 12卷 / 04期

关键词：

advanced colorectal cancer; BRAF mutation; DNA mismatch repair deficiency; high microsatellite instability; immunotherapy; PD-1; inhibitors; MICROSATELLITE INSTABILITY; BRAF MUTATION; OPEN-LABEL; VEMURAFENIB; IRINOTECAN; CETUXIMAB; TRIAL;

D O I：

10.2217/imt-2019-0148

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Metastatic colorectal cancer with BRAF mutation is a type of highly invasive malignant tumor with poor prognosis and few treatment options. Here, we report a case of a BRAF-mutant and DNA mismatch-repair deficiency colorectal cancer patient with postoperative recurrence as well as abdominal cavity and pelvic metastasis, whose condition was relieved continuously after treatment with a new anti-PD-1 antibody, BGB-A317.

引用

页码：229 / 234

页数：6

共 21 条

[1]

[Anonymous], 2016, ANN ONCOL

[2]

[Anonymous], 2015, J GREY SYST UK

[3] BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment? [J].

Cohen, Romain ;

Cervera, Pascale ;

Svrcek, Magali ;

Pellat, Anna ;

Dreyer, Chantal ;

de Gramont, Aimery ;

Andre, Thierry .

CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (02)

[4] FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study [J].

Cremolini, Chiara ;

Loupakis, Fotios ;

Antoniotti, Carlotta ;

Lupi, Cristiana ;

Sensi, Elisa ;

Lonardi, Sara ;

Mezi, Silvia ;

Tomasello, Gianluca ;

Ronzoni, Monica ;

Zaniboni, Alberto ;

Tonini, Giuseppe ;

Carlomagno, Chiara ;

Allegrini, Giacomo ;

Chiara, Silvana ;

D'Amico, Mauro ;

Granetto, Cristina ;

Cazzaniga, Marina ;

Boni, Luca ;

Fontanini, Gabriella ;

Falcone, Alfredo .

LANCET ONCOLOGY, 2015, 16 (13) :1306-1315

[5] The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab [J].

Feng, Yingcai ;

Hong, Yuan ;

Sun, Hanzi ;

Zhang, Bo ;

Wu, Hongfu ;

Li, Kang ;

Liu, Xuesong ;

Liu, Ye .

CANCER RESEARCH, 2019, 79 (13)

[6] Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J].

Ferlay, Jacques ;

Soerjomataram, Isabelle ;

Dikshit, Rajesh ;

Eser, Sultan ;

Mathers, Colin ;

Rebelo, Marise ;

Parkin, Donald Maxwell ;

Forman, David ;

Bray, Freddie .

INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) :E359-E386

[7] Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer [J].

Kopetz, S. ;

Grothey, A. ;

Yaeger, R. ;

Van Cutsem, E. ;

Desai, J. ;

Yoshino, T. ;

Wasan, H. ;

Ciardiello, F. ;

Loupakis, F. ;

Hong, Y. S. ;

Steeghs, N. ;

Guren, T. K. ;

Arkenau, H. -T. ;

Garcia-Alfonso, P. ;

Pfeiffer, P. ;

Orlov, S. ;

Lonardi, S. ;

Elez, E. ;

Kim, T. -W. ;

Schellens, J. H. M. ;

Guo, C. ;

Krishnan, A. ;

Dekervel, J. ;

Morris, V. ;

Calvo Ferrandiz, A. ;

Tarpgaard, L. S. ;

Braun, M. ;

Gollerkeri, A. ;

Keir, C. ;

Maharry, K. ;

Pickard, M. ;

Christy-Bittel, J. ;

Anderson, L. ;

Sandor, V. ;

Tabernero, J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (17) :1632-1643

[8]

Kopetz S, 2017, J CLIN ONCOL, V35

[9] Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer [J].

Kopetz, Scott ;

Desai, Jayesh ;

Chan, Emily ;

Hecht, Joel Randolph ;

O'Dwyer, Peter J. ;

Maru, Dipen ;

Van Morris ;

Janku, Filip ;

Dasari, Arvind ;

Chung, Woonbook ;

Issa, Jean-Pierre J. ;

Gibbs, Peter ;

James, Brian ;

Powis, Garth ;

Nolop, Keith B. ;

Bhattacharya, Suman ;

Saltz, Leonard .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) :4032-4038

[10] PD-1 Blockade in Tumors with Mismatch-Repair Deficiency [J].

Le, D. T. ;

Uram, J. N. ;

Wang, H. ;

Bartlett, B. R. ;

Kemberling, H. ;

Eyring, A. D. ;

Skora, A. D. ;

Luber, B. S. ;

Azad, N. S. ;

Laheru, D. ;

Biedrzycki, B. ;

Donehower, R. C. ;

Zaheer, A. ;

Fisher, G. A. ;

Crocenzi, T. S. ;

Lee, J. J. ;

Duffy, S. M. ;

Goldberg, R. M. ;

de la Chapelle, A. ;

Koshiji, M. ;

Bhaijee, F. ;

Huebner, T. ;

Hruban, R. H. ;

Wood, L. D. ;

Cuka, N. ;

Pardoll, D. M. ;

Papadopoulos, N. ;

Kinzler, K. W. ;

Zhou, S. ;

Cornish, T. C. ;

Taube, J. M. ;

Anders, R. A. ;

Eshleman, J. R. ;

Vogelstein, B. ;

Diaz, L. A., Jr. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (26) :2509-2520

← 1 2 3 →